EU's IMI to collaborate with FDA’s Critical Path

15.06.2011
EU's IMI to collaborate with FDA’s Critical Path
Science Business

Europe’s Innovative Medicines Initiative (IMI) is joining forces with its US counterpart, the Critical Path Institute (C-Path) to further their shared mission of reshaping the drug development process to improve the productivity of pharmaceutical industry R&D.

Read more on Science Business website